LeMaitre Vascular (NASDAQ:LMAT) Issues Quarterly Earnings Results

LeMaitre Vascular (NASDAQ:LMAT) issued its quarterly earnings results on Wednesday. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.69 by ($0.04), FiscalAI reports. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. During the same quarter last year, the business earned $0.75 earnings per share. The company’s revenue was up 11.3% on a year-over-year basis.

Here are the key takeaways from LeMaitre Vascular’s conference call:

• Q3 organic sales grew 12%, driven by 7% pricing and 5% unit growth, with gains across products and regions. LeMaitre reiterated 11% full-year organic growth guidance and expects adjusted EPS to rise 18% to $2.80.
• The B. Braun acquisition adds vascular grafts and other devices with $9.4 million in 2025 sales, but the commercial transition is expected to take 18–24 months. LeMaitre warned of potential customer losses during the transition and expects to record only about $150,000 of related revenue in Q4.
• RestoreFlow revenue grew 34%, including 65% growth in cardiac tissue, but quality-control processing constraints are limiting how much product the company can release and sell. Management said the bottleneck may persist for a while as it adds resources to address it.
• Full-year operating-margin guidance is 27%, with the outlook reduced by about $1.4 million, reflecting the FAS-TIP inventory reserve, faster sales-force and infrastructure investment, RestoreFlow transfer costs, and foreign-exchange pressure. Q3 operating expenses rose 18% year over year.

LeMaitre Vascular Stock Performance

LMAT stock traded up $7.32 during trading hours on Wednesday, reaching $87.92. The stock had a trading volume of 514,878 shares, compared to its average volume of 271,336. The stock has a market capitalization of $2.01 billion, a PE ratio of 29.63, a price-to-earnings-growth ratio of 2.32 and a beta of 0.51. The company has a debt-to-equity ratio of 0.40, a current ratio of 16.31 and a quick ratio of 13.96. The stock has a 50-day simple moving average of $81.38 and a 200 day simple moving average of $94.16. LeMaitre Vascular has a fifty-two week low of $78.22 and a fifty-two week high of $118.01.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Wells Fargo & Company lowered their target price on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 5th. Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings downgraded LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 23rd. Three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $110.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.